Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
•
Diabetes
•
Endocrinology
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
Related Questions
What are your top takeaways in GU Cancers from ESMO 2024?
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
What is your approach to muscle-invasive bladder cancer in a patient who is ineligible for surgery and radiotherapy?
Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?
Under what circumstances would it be appropriate to offer trimodality therapy (TMT) in muscle-invasive bladder cancer with localized variant histology?
What is the optimal approach to systemic therapy for metastatic squamous cell carcinoma of the bladder considering the approval of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma?
Is there a clinical benefit for a repeat TURBT to ensure complete resection of the bladder tumor prior to neoadjuvant chemotherapy and radical cystectomy?
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
How do you manage dysgeusia from Enfortumab Vedotin?
